Stem Cell Therapy International Announces the Successful Treatment of Stroke Victim Who Received Stem Cell Transplantation Therapy
Stem Cell Therapy International, Inc. (OTC: SCII), a leading company in the field of research and development of stem cell transplantation (SCT) therapy and regenerative medicine, announced today the successful results of a case of stem cell transplantation recently concluded in Kiev, Ukraine, on Ian McBride, 49, a stroke victim from Belfast, Ireland.
Article
ReNeuron Group plc Demonstrates Key Characteristics with its Hepatocyte (liver) Cell Lines for Drug Discovery Applications
ReNeuron Group plc (LSE: RENE.L) today announced that it has developed human hepatocyte (liver) cell lines using its proprietary c-mycERTAM platform technology.
Article
European Commission Approves Kepivance(TM) (Palifermin) for Oral Mucositis in Cancer Patients Undergoing Blood and Bone Marrow Transplant
Amgen (Nasdaq:AMGN), the world’s largest biotechnology company, today announced that Kepivance(TM) (palifermin) has received regulatory approval in the European Union (EU).
Article
Sigma-Aldrich Corporation (SIAL) Strengthens Position In RNAi Through Licensing And Equity Positions In Benitec Limited (BLT.AX) And Oxford BioMedica PLC (OXB.L)
Sigma-Aldrich, a leading $1.4 billion Life Science company announced today that it has signed a series of agreements that expand its position in the area of RNA Interference (RNAi).
Article
BioWa and OncoTherapy Science Announce Collaboration to Develop Anticancer Monoclonal Antibodies With Enhanced ADCC
BioWa, Inc. and OncoTherapy Science, Inc. today announced that the two companies have entered into a collaboration to identify and develop cancer- focused monoclonal antibodies (Mabs).
Article
Chromos Molecular Systems Inc. (CHR.TO) Enters Definitive Agreement To Acquire Targeted Molecules Corporation; Secures Financing Commitments
Chromos Molecular Systems Inc. (“Chromos”) (TSX:CHR) announced today that it has entered into a definitive agreement under which it will acquire Targeted Molecules Corporation (“TMC”), a privately held San Diego based biotechnology company focused on the research and development of two antibody product candidates for treatment of multiple sclerosis (MS) and acute thrombosis.
Article
ChondroGene Inc. (CDG.V) Enters Into Agreement With Kaiser Permanente
ChondroGene Limited announced today that it has entered into an agreement with the Division of Research of the Permanente Medical Group of Northern California, to jointly develop a research database infrastructure that will be used for genomic research.
Article
GE Healthcare Introduces ÄKTAprocess – A Flexible Chromatography System for Fast and Efficient Purification at Process Scale
GE Healthcare, a unit of General Electric Company (NYSE: GE), introduced today the ÄKTAprocess low pressure liquid chromatography system for accurate, and reproducible purification in downstream processing. ÄKTAprocess is a configurable manufacturing system that promotes process efficiency and reliability, and complies with regulatory requirements.
Article
U.S. BioDefense, Inc. (UBDF.OB) Option Agreement With The University of Minnesota Ended
U.S. BioDefense, Inc. announced today that its Option Agreement to license United States Patent Application No. 6,485,722 B1 entitled “Method for Selective Engraftment of Drug-Resistant Hematopoietic Stem Cells” and related applications was unilaterally terminated by University of Minnesota.
Article
ViaCell, Inc. Announces Settlement Of Litigation With Cord Blood Registry
ViaCell, Inc. announced today that it has entered into an agreement to settle pending litigation with CBR Systems, Inc.
Article
Hemosol (HMSL) Cuts Two-Thirds Of Staff To Conserve Cash
Hemosol Corp. (NASDAQ: HMSL, TSX: HML) today announced that it has served approximately two thirds of its employees with layoff notices.
Article
ViRexx Appoints Dr. Lorne Tyrrell Chief Executive Officer
ViRexx Medical Corp. (TSX:VIR), a company focused on immunotherapy treatments for cancer, chronic hepatitis B & C and embolotherapy treatments for tumors today announced that Dr. Lorne Tyrrell has been named the Company’s Chief Executive Officer by the Board of Directors effective November 1, 2005.
Article
PharmaFrontiers Corp. Elects Interim Chairman
PharmaFrontiers Corp. (OTCBB:PFTR), a company involved in the development and commercialization of cell therapies, announced today that Brooks Boveroux, a director of the Company, has been unanimously elected interim chairman of the board, effective immediately.
Article